QIBA PET-Amyloid Biomarker Committee
Friday, March 11, 2022, at **9 AM CT**
Call Summary

In attendance:		RSNA
Anne M. Smith, PhD (Co-chair)	Adriaan Lammertsma, PhD	Joe Koudelik
Dawn Matthews, MS, MBA (co-chair)	Peter Ngum, MSc	Julie Lisiecki
Orest Boyko, MD, PhD	Nancy Obuchowski, PhD	
Rachid Fahmi, MSc, PhD	Jean-Luc Vanderheyden, PhD	
Clara Ferreira	Dean F. Wong, MD, PhD	
Norman Foster, MD		

Moderator: Dr. Smith

The following were discussed:
- Manuscript was submitted to SNMMI's *The Journal of Nuclear Medicine* (JNM) on 2/16
- Reviewed specific recommended changes to address technical confirmation questionnaire site feedback
- Outstanding items on questionnaire were reviewed and refined through group discussion, to be implemented in Profile and its checklist
- Technical Confirmation vote planned once changes are incorporated and posted
- Recent insights from the field regarding Amyloid PET usage and standardization were discussed

Next steps
- Ms. Matthews to provide: (1) updated Profile, (2) marked up Profile, (3) updated Checklist, and (4) a document summarizing agreed upon Profile changes (for wiki posting)
- Move forward to Technical Confirmation vote at BC level (and later CC level)
  - RSNA Staff to prepare e-ballot for Technical Confirmation vote, with two-week deadline
- Opportunity for the Profile to be used to standardize PET Amyloid imaging
  - New methods are being sought for clinical trials
  - Researchers seek to determine what is the amyloid PET scan that should be used to stop treatment
  - Standardization per the QIBA Profile may be used to aid with these decisions
- Challenges of the use of amyloid PET as a treatment response biomarker (more discussion needed)
  - Lack of access to treatments for rural locations and underrepresented minorities
  - Delay between amyloid clearance (from the brain) and stabilization (of brain function)
- A practical method will be needed to indicate which PET centers are best suited to quantification

Action items (ongoing) *- please strike those that are complete*
- Produce an online questionnaire with scoring capability, modeled after FDG-PET BC
- CMS decision for final coverage to be announced on April 11, 2022
- Dr. Smith to provide speaker suggestions for PET Amyloid presentation at SNMMI to Dr. Zahlmann
- Drs. Wong and Smith to ask the SNMMI brain imaging council to consider providing an endorsement
- Consider contacting EANM neuroimaging committee
- Dr. Lammertsma to share citations from Alzheimer's research
- Co-chairs to respond to Mr. O'Donnell's suggestions
- Following preparation for Technical Confirmation:
  - Ms. Matthews to list key highlights for the best opportunities for harmonization: recommendations requested
  - Ms. Matthews and Dr. Foster to schedule a call with Dr. Koeppe to discuss the ADNI-QIBA gap analysis
    - Dr. Wong to be included
  - Ms. Matthews to reach out to Dr. Seibyl regarding introduction to Invicro
  - BC discussion on how to handle resistance to Profile requirements

Next calls – April 15th at 9 am CT; May 13th at 9 am CT